← 產業報告目錄

Allergy Diagnostic Market by Product & Service (Consumables, Instruments [Immunoassay Analyzers, Luminometers]), Test Type (In Vivo Tests, In Vitro Tests), Allergen (Food Allergens), End User (Hospital-Based Laboratories) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-02-17頁數 257報告編號 MD2955

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The allergy diagnostic market is projected to reach USD 10.77 billion by 2030 from USD 6.80 billion in 2025, at a CAGR of 9.6% during the forecast period. Technological innovation in allergy diagnostics is a key driver of growth, making testing more accurate, faster, and comprehensive. Traditional diagnostic methods such as skin prick tests (SPT) and single, allergen blood IgE tests are still of use, but the advanced platforms like multiplex immunoassays, component resolved diagnostics (CRD), and molecular allergology have surpassed them in a variety of ways. Multiplex platforms allow simultaneous detection of IgE responses to dozens or even hundreds of allergens in a single sample, thereby decreasing the time, cost, and effort for the patient. CRD is a step further in that it pinpoints the exact protein molecules within the allergens that are the cause of sensitization, thus increasing how clinically relevant the test is and risk stratification; e.g. , it can differentiate between innocent pollen sensitization and cross-reactivity that is a predictor of severe reactions. Molecular diagnostics are also instrumental in personalized medicine—they generate the individual sensitization profile map, which doctors use for the personalization of immunotherapy treatments. Automation and digital integration with electronic health records facilitate the working processes in clinical laboratories and are also of assistance when it comes to undertaking large-scale screening programs. Point-of-care (POC) innovations that deliver quick results right in doctors' or pharmacies' offices enhance patients' convenience and the effectiveness of medical care. Apart from that, AI-powered interpretation tools are being developed to help doctors make sense of complicated allergen profiles. Such technological innovations not only improve test performance and patient experience but also represent a long-term market expansion in which diagnostic precision becomes the standard of care. Based on product & service: The global increase in allergic diseases is a significant factor that explains why consumables have the leading share in the allergy diagnostic market. A combination of factors such as the explosive growth of cities, the deterioration of the environment, alterations in lifestyles, changes in diet, and global warming has, among other things, led to a rise in food allergies, allergic rhinitis, asthma, and atopic dermatitis. Correspondingly, the growing patient population results in higher diagnostic testing volumes, particularly laboratory-based in vitro tests, which are highly dependent on consumables. Numerous reagents and allergen-specific kits are required for each diagnostic episode; thus, the demand for consumables is further increased. Besides that, both children and elderly pediatric and geriatric populations are among the most susceptible to allergies and, therefore, often necessitate repeated and confirmatory tests. Consumables remain the most directly affected and fastest-growing source of revenue as the disease burden escalates worldwide, especially in the Asia Pacific and emerging markets. Based on test type: A powerful incentive for the widespread adoption of in vivo testing, among other things, is the possibility of delivering test results within 15–30 minutes during a single patient visit. Such instant feedback enables doctors to identify allergies, advise patients, and start therapy plans right away. In vivo tests offer a workflow that is much more efficient, with rapid diagnosis compared to in vitro tests, which are subjected to laboratory processing and require a longer turnaround time. Besides patient satisfaction, fast diagnosis is important because it reduces patient revisits, both of which factors make the tests more appealing to outpatient clinics and hospital settings, thereby leading to higher utilization and market share for these tests. North America holds the largest market share in the allergy diagnostic market. The North American region has a sophisticated healthcare ecosystem that strongly promotes the use of allergy diagnostics at scale. The area is well-equipped with a variety of hospitals, specialty allergy clinics, diagnostic laboratories, and reference labs equipped with advanced testing equipment. The presence of automated immunoassay analyzers, multiplex testing systems, and centralized lab services ensures high test accuracy and speed. In addition, the diagnostics are so well integrated into clinical workflows that doctors can easily order allergy tests as standard of care, thereby supporting the market leader's dominance. A breakdown of the primary participants (supply-side) for the allergy diagnostic market referred to in this report is provided below: • By Company Type: Tier 1: 34%, Tier 2: 38%, and Tier 3: 28% • By Designation: C-level: 26%, Director Level: 35%, and Others: 39% • By Region: North America: 35%, Europe: 30%, Asia Pacific: 25%, Latin America: 6%, Middle East & Africa: 2%, GCC Countries: 3% Prominent players in the allergy diagnostic market are Thermo Fisher Scientific Inc. (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Minaris Medical America, Inc. (US), Omega Diagnostics Group Plc (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (Germany), HollisterStier Allergy (US), Eurofins Scientific (Luxembourg), and Stallergenes Greer (UK), among others. Research Coverage The report evaluates the allergy diagnostic market and estimates its size and future growth potential across various segments, including product & service, test type, allergen, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies. Reasons to Buy the Report The report provides valuable data on estimated revenue figures for the overall allergy diagnostic market and its subsegments, benefiting both market leaders and new entrants. It helps stakeholders understand the competitive landscape and gain insights for effectively positioning their businesses and developing appropriate go-to-market strategies. Additionally, the report offers stakeholders an understanding of market trends, including key drivers, challenges, obstacles, and opportunities within the market. This report provides insights into the following points:  Analysis of key drivers (High incidence and heavy economic burden of allergic diseases, Increasing awareness about allergies, Rising environmental pollution levels, Coverage of allergy diagnosis under health insurance schemes), restraints (Premium cost of allergy diagnostic instruments, Lack of adequate knowledge and poor implementation of allergy testing methods, Limited access to healthcare services), opportunities (Limited access to healthcare services, Integration of artificial intelligence in allergy diagnosis), and challenges (Shortage of allergists and lack of training programs, Diagnostic challenges in allergic patients) • Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global allergy diagnostic market • Market Development: Thorough knowledge and analysis of the profitable rising markets by product & service, test type, allergen, end user, and region • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global allergy diagnostic market • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global allergy diagnostic market
目錄 Table of Contents
1 INTRODUCTION 27 1.1 STUDY OBJECTIVES 27 1.2 MARKET DEFINITION 27 1.2.1 INCLUSIONS & EXCLUSIONS 28 1.3 STUDY SCOPE 29 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 29 1.3.2 YEARS CONSIDERED 30 1.3.3 CURRENCY CONSIDERED 30 1.4 STAKEHOLDERS 30 1.5 SUMMARY OF CHANGES 31 2 EXECUTIVE SUMMARY 32 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 32 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND DEVELOPMENTS 34 2.3 DISRUPTIVE TRENDS SHAPING MARKET 35 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 36 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 37 3 PREMIUM INSIGHTS 38 3.1 ALLERGY DIAGNOSTIC MARKET OVERVIEW 38 3.2 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY END USER AND COUNTRY 39 3.3 ALLERGY DIAGNOSTIC MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 40 3.4 ALLERGY DIAGNOSTIC MARKET: REGIONAL MIX 41 3.5 ALLERGY DIAGNOSTIC MARKET: DEVELOPED VS. EMERGING ECONOMIES 41 4 MARKET OVERVIEW 42 4.1 INTRODUCTION 42 4.2 MARKET DYNAMICS 42 4.2.1 DRIVERS 43 4.2.1.1 High incidence and heavy economic burden of allergic diseases 43 4.2.1.2 Increasing awareness about allergies 43 4.2.1.3 Rising environmental pollution levels 44 4.2.1.4 Coverage of allergy diagnosis under health insurance schemes 44 4.2.2 RESTRAINTS 45 4.2.2.1 Premium cost of allergy diagnostic instruments 45 4.2.2.2 Lack of adequate knowledge and poor implementation of allergy testing methods 45 4.2.2.3 Limited access to healthcare services 46   4.2.3 OPPORTUNITIES 46 4.2.3.1 Use of mHealth in allergy diagnosis 46 4.2.3.2 Integration of artificial intelligence in allergy diagnosis 47 4.2.4 CHALLENGES 47 4.2.4.1 Shortage of allergists and lack of training programs 47 4.2.4.2 Diagnostic challenges in allergic patients 48 4.3 UNMET NEEDS & WHITE SPACES 48 4.3.1 UNMET NEEDS IN ALLERGY DIAGNOSTIC MARKET 48 4.3.2 WHITE SPACE OPPORTUNITIES 49 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50 4.4.1 INTERCONNECTED MARKETS 50 4.4.2 CROSS-SECTOR OPPORTUNITIES 50 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 51 5 INDUSTRY TRENDS 52 5.1 PORTER’S FIVE FORCES ANALYSIS 52 5.1.1 INTENSITY OF COMPETITIVE RIVALRY 53 5.1.2 BARGAINING POWER OF SUPPLIERS 53 5.1.3 BARGAINING POWER OF BUYERS 54 5.1.4 THREAT OF SUBSTITUTES 54 5.1.5 THREAT OF NEW ENTRANTS 54 5.2 MACROECONOMIC OUTLOOK 54 5.2.1 INTRODUCTION 54 5.2.2 GDP TRENDS AND FORECAST 54 5.2.3 TRENDS IN GLOBAL IVD INDUSTRY 56 5.2.4 TRENDS IN GLOBAL IMMUNOASSAY INDUSTRY 56 5.3 SUPPLY CHAIN ANALYSIS 57 5.4 VALUE CHAIN ANALYSIS 58 5.5 ECOSYSTEM ANALYSIS 59 5.6 PRICING ANALYSIS 59 5.6.1 AVERAGE SELLING PRICE OF ALLERGY DIAGNOSTIC PRODUCTS, BY PRODUCT & SERVICE, 2025 59 5.6.2 AVERAGE SELLING PRICE TREND OF ALLERGY DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026 60 5.7 TRADE ANALYSIS 61 5.7.1 IMPORT DATA FOR HS CODE 902750, 2020–2024 61 5.7.2 EXPORT DATA FOR HS CODE 902750, 2020–2024 62 5.8 KEY CONFERENCES & EVENTS, 2026–2027 62 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 63 5.10 INVESTMENT & FUNDING SCENARIO 64   5.11 CASE STUDY ANALYSIS 64 5.11.1 EXPANDING ACCESS TO ALLERGY DIAGNOSTICS IN EMERGING MARKETS 64 5.11.2 SCALING HIGH-THROUGHPUT ALLERGY TESTING IN CENTRALIZED LABORATORIES 65 5.11.3 IMPROVING PEDIATRIC ALLERGY DIAGNOSIS THROUGH MULTIPLEX TESTING 65 5.12 IMPACT OF 2025 US TARIFF ON ALLERGY DIAGNOSTIC MARKET 65 5.12.1 INTRODUCTION 65 5.12.2 KEY TARIFF RATES 66 5.12.3 PRICE IMPACT ANALYSIS 67 5.12.4 IMPACT ON COUNTRIES/REGIONS 67 5.12.4.1 North America 67 5.12.4.2 Europe 67 5.12.4.3 Asia Pacific 67 5.12.5 END-USE INDUSTRY IMPACT 68 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 69 6.1 KEY EMERGING TECHNOLOGIES 69 6.1.1 SPECIFIC IGE IMMUNOASSAYS 69 6.1.2 SKIN PRICK TESTING (SPT) 69 6.2 COMPLEMENTARY TECHNOLOGIES 69 6.2.1 AUTOMATED IMMUNOASSAY ANALYZERS 69 6.3 TECHNOLOGY/PRODUCT ROADMAP 70 6.3.1 SHORT-TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 70 6.3.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 70 6.3.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 71 6.4 PATENT ANALYSIS 72 6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 72 6.5 FUTURE APPLICATIONS 73 6.5.1 ADVANCED MULTIPLEX AND PERSONALIZED ALLERGY DIAGNOSTICS 73 6.5.2 DIGITAL & AI-ENABLED ALLERGY MONITORING PLATFORMS 74 6.5.3 AI-INTEGRATED DIGITAL SURGICAL ECOSYSTEMS FOR IOLS 74 6.6 IMPACT OF AI/GEN AI ON ALLERGY DIAGNOSTIC MARKET 75 6.6.1 TOP USE CASES AND MARKET POTENTIAL 75 6.6.2 CASE STUDIES OF AI IMPLEMENTATION 75 6.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 76 6.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI 77   7 REGULATORY LANDSCAPE 78 7.1 REGIONAL REGULATIONS & COMPLIANCE 78 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 7.1.2 INDUSTRY STANDARDS 80 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 81 8.1 DECISION-MAKING PROCESS 81 8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA 81 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 81 8.2.2 KEY BUYING CRITERIA 82 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 83 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 83 8.5 MARKET PROFITABILITY 84 8.5.1 REVENUE POTENTIAL 84 8.5.2 COST DYNAMICS 84 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 84 9 ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE 85 9.1 INTRODUCTION 86 9.2 CONSUMABLES 86 9.2.1 RECURRENT USE OF CONSUMABLES FOR ALLERGY DIAGNOSTICS TO DRIVE MARKET 86 9.3 INSTRUMENTS 87 9.3.1 IMMUNOASSAY ANALYZERS 89 9.3.1.1 High preference for testing to boost market demand 89 9.3.2 LUMINOMETERS 91 9.3.2.1 Convenience and ease of use to propel market growth 91 9.3.3 OTHER INSTRUMENTS 92 9.4 SERVICES 94 9.4.1 RISING NEED TO ENSURE EFFECTIVE UTILIZATION OF ALLERGY DIAGNOSTIC PRODUCTS TO SUPPORT MARKET GROWTH 94 10 ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE 95 10.1 INTRODUCTION 96 10.2 IN VIVO TESTS 97 10.2.1 SKIN PRICK TESTS 98 10.2.1.1 Skin prick tests to be most widely preferred in vivo allergy tests 98 10.2.2 PATCH TESTS 99 10.2.2.1 Rapid diagnosis of contact dermatitis to boost market demand 99 10.2.3 OTHER IN VIVO TESTS 100   10.3 IN VITRO TESTS 102 10.3.1 ABILITY TO IDENTIFY ALLERGEN-SPECIFIC IGE MOLECULES IN PATIENT SERUM TO DRIVE MARKET 102 11 ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN 104 11.1 INTRODUCTION 105 11.2 INHALED ALLERGENS 105 11.2.1 HIGH INCIDENCE OF ASTHMA TO BOOST MARKET GROWTH 105 11.3 FOOD ALLERGENS 106 11.3.1 HIGH PREVALENCE OF FOOD-RELATED ALLERGIES AMONG YOUNG CHILDREN TO SUPPORT MARKET GROWTH 106 11.4 DRUG ALLERGENS 108 11.4.1 INCREASING INCIDENCE OF DRUG ALLERGIES AND ADVERSE REACTIONS TO DRIVE MARKET 108 11.5 OTHER ALLERGENS 109 12 ALLERGY DIAGNOSTIC MARKET, BY END USER 111 12.1 INTRODUCTION 112 12.2 HOSPITAL-BASED LABORATORIES 112 12.2.1 HOSPIATAL-BASED LABORATORIES TO BE MORE ACCESSIBLE TO PATIENTS AND OFFER RAPID RESULTS 112 12.3 DIAGNOSTIC LABORATORIES 114 12.3.1 DIAGNOSTIC LABORATORIES TO PIVOTAL FOR DIAGNOSIS AND MANAGEMENT OF ALLERGIES 114 12.4 ACADEMIC RESEARCH INSTITUTES 116 12.4.1 RISING NUMBER OF INSTITUTES FOR ALLERGY TESTING TRAINING TO SUPPORT MARKET GROWTH 116 12.5 OTHER END USERS 118 13 ALLERGY DIAGNOSTIC MARKET, BY REGION 119 13.1 INTRODUCTION 120 13.2 NORTH AMERICA 120 13.2.1 US 124 13.2.1.1 US to dominate North American allergy diagnostic market 124 13.2.2 CANADA 127 13.2.2.1 Rising funding activities in allergy diagnostics to drive market 127 13.3 EUROPE 129 13.3.1 GERMANY 132 13.3.1.1 Increasing prevalence of allergic conditions and rising presence of allergy diagnostic product manufacturers to aid market growth 132 13.3.2 UK 134 13.3.2.1 Increasing prevalence of food anaphylaxis to support market growth 134 13.3.3 FRANCE 137 13.3.3.1 Increasing reimbursements for allergy testing to spur market growth 137 13.3.4 ITALY 140 13.3.4.1 Presence of allergy diagnostic organizations to support increased demand for products 140 13.3.5 SPAIN 142 13.3.5.1 Government initiatives and healthcare infrastructural development to drive market 142 13.3.6 REST OF EUROPE 145 13.4 ASIA PACIFIC 147 13.4.1 CHINA 151 13.4.1.1 Rising allergy prevalence and growing research activities to augment market growth 151 13.4.2 JAPAN 153 13.4.2.1 Increasing prevalence of allergies among children to propel demand for allergy diagnostics 153 13.4.3 INDIA 156 13.4.3.1 Limited awareness regarding allergy management to limit market growth 156 13.4.4 SOUTH KOREA 159 13.4.4.1 Rising allergy burden and high diagnostic uptake to fuel South Korean market growth 159 13.4.5 AUSTRALIA 161 13.4.5.1 High prevalence of food allergies and major lifestyle changes to drive market 161 13.4.6 REST OF ASIA PACIFIC 164 13.5 LATIN AMERICA 167 13.5.1 BRAZIL 169 13.5.1.1 High prevalence of childhood asthma to augment market growth 169 13.5.2 MEXICO 172 13.5.2.1 Growing focus on awareness training programs to boost market demand 172 13.5.3 REST OF LATIN AMERICA 174 13.6 MIDDLE EAST & AFRICA 177 13.7 GCC COUNTRIES 180 13.7.1 RISING HEALTHCARE SPENDING TO SPUR MARKET GROWTH 180 14 COMPETITIVE LANDSCAPE 183 14.1 INTRODUCTION 183 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN 183 14.3 REVENUE ANALYSIS, 2021–2025 184 14.4 MARKET SHARE ANALYSIS 185 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 187 14.5.1 STARS 187 14.5.2 EMERGING LEADERS 187 14.5.3 PERVASIVE PLAYERS 187 14.5.4 PARTICIPANTS 187 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 189 14.5.5.1 Company footprint 189 14.5.5.2 Region footprint 189 14.5.5.3 Product & service footprint 190 14.5.5.4 Test type footprint 191 14.5.5.5 Allergen footprint 191 14.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2025 192 14.6.1 PROGRESSIVE COMPANIES 192 14.6.2 RESPONSIVE COMPANIES 192 14.6.3 DYNAMIC COMPANIES 192 14.6.4 STARTING BLOCKS 192 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 193 14.6.5.1 Detailed list of key startups/SMEs 193 14.6.5.2 Competitive benchmarking of startups/SMEs 194 14.7 COMPANY VALUATION & FINANCIAL METRICS 195 14.7.1 FINANCIAL METRICS 195 14.7.2 COMPANY VALUATION 195 14.8 BRAND/PRODUCT COMPARISON 196 14.9 COMPETITIVE SCENARIO 196 14.9.1 PRODUCT LAUNCHES & APPROVALS 196 14.9.2 DEALS 197 14.9.3 EXPANSIONS 198 15 COMPANY PROFILES 199 15.1 KEY PLAYERS 199 15.1.1 THERMO FISHER SCIENTIFIC INC. 199 15.1.1.1 Business overview 199 15.1.1.2 Products offered 200 15.1.1.3 Recent developments 201 15.1.1.3.1 Product launches & approvals 201 15.1.1.3.2 Deals 201 15.1.1.4 MnM view 201 15.1.1.4.1 Right to win 201 15.1.1.4.2 Strategic choices 201 15.1.1.4.3 Weaknesses & competitive threats 202 15.1.2 DANAHER CORPORATION 203 15.1.2.1 Business overview 203 15.1.2.2 Products offered 204 15.1.2.3 MnM view 205 15.1.2.3.1 Right to win 205 15.1.2.3.2 Strategic choices 205 15.1.2.3.3 Weaknesses & competitive threats 205 15.1.3 SIEMENS HEALTHINEERS AG 206 15.1.3.1 Business overview 206 15.1.3.2 Products offered 207 15.1.3.3 MnM view 208 15.1.3.3.1 Right to win 208 15.1.3.3.2 Strategic choices 208 15.1.3.3.3 Weaknesses & competitive threats 208 15.1.4 CANON, INC. (MINARIS MEDICAL AMERICA, INC.) 209 15.1.4.1 Business overview 209 15.1.4.2 Products offered 210 15.1.4.3 Recent developments 211 15.1.4.3.1 Deals 211 15.1.4.4 MnM view 211 15.1.4.4.1 Right to win 211 15.1.4.4.2 Strategic choices 211 15.1.4.4.3 Weaknesses & competitive threats 211 15.1.5 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG) 212 15.1.5.1 Business overview 212 15.1.5.2 Products offered 213 15.1.5.3 Recent developments 214 15.1.5.3.1 Deals 214 15.1.5.4 MnM view 214 15.1.5.4.1 Right to win 214 15.1.5.4.2 Strategic choices 214 15.1.5.4.3 Weaknesses & competitive threats 214 15.1.6 EUROFINS SCIENTIFIC 215 15.1.6.1 Business overview 215 15.1.6.2 Products offered 216 15.1.6.3 Recent developments 217 15.1.6.3.1 Expansions 217 15.1.7 BIOMÉRIEUX SA 218 15.1.7.1 Business overview 218 15.1.7.2 Products offered 219 15.1.8 DSM ROYAL (ROMER LABS DIVISION HOLDING GMBH) 220 15.1.8.1 Business overview 220 15.1.8.2 Products offered 221 15.1.8.3 Recent developments 222 15.1.8.3.1 Deals 222 15.1.9 HOLLISTERSTIER ALLERGY (JUBILANT PHARMA) 223 15.1.9.1 Business overview 223 15.1.9.2 Products offered 224 15.1.10 OMEGA DIAGNOSTICS GROUP PLC 225 15.1.10.1 Business overview 225 15.1.10.2 Products offered 226 15.1.11 STALLERGENES GREER LTD. 227 15.1.11.1 Business overview 227 15.1.11.2 Products offered 227 15.1.11.3 Recent developments 227 15.1.11.3.1 Deals 227 15.2 OTHER PLAYERS 228 15.2.1 HOB BIOTECH GROUP CORP., LTD. 228 15.2.2 HYCOR BIOMEDICAL 228 15.2.3 LINCOLN DIAGNOSTICS, INC. 229 15.2.4 R-BIOPHARM AG 230 15.2.5 ASTRA BIOTECH GMBH 231 15.2.6 ERBA GROUP 231 15.2.7 AESKU.GROUP GMBH 232 15.2.8 ACON LABORATORIES, INC. 232 15.2.9 ALCIT INDIA PVT. LTD. 233 15.2.10 BIOPANDA REAGENTS LTD. 233 15.2.11 BIOSIDE S.R.L. 234 15.2.12 CREATIVE DIAGNOSTIC MEDICARE PVT. LTD. 234 15.2.13 DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH 235 15.2.14 DR. FOOKE LABORATORIEN GMBH 235 16 RESEARCH METHODOLOGY 236 16.1 RESEARCH DATA 236 16.1.1 SECONDARY DATA 236 16.1.1.1 Key secondary sources 237 16.1.1.2 Key data from secondary sources 238 16.1.2 PRIMARY DATA 238 16.1.2.1 Objectives of primary research 239 16.1.2.2 Key data from primary sources 239 16.1.2.3 Key industry insights 240 16.1.2.4 Breakdown of primaries 240 16.2 MARKET SIZE ESTIMATION 242 16.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 242 16.2.2 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS 244 16.2.3 TOP-DOWN APPROACH 244 16.2.4 DEMAND-SIDE ANALYSIS 244 16.3 DATA TRIANGULATION 247 16.4 MARKET SHARE ESTIMATION 248 16.5 STUDY ASSUMPTIONS 248 16.6 RISK ANALYSIS 248 16.7 RESEARCH LIMITATIONS 249 17 APPENDIX 250 17.1 DISCUSSION GUIDE 250 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS. SUBSCRIPTION PORTAL 253 17.3 CUSTOMIZATION OPTIONS 255 17.4 RELATED REPORTS 255 17.5 AUTHOR DETAILS 256
圖表清單 List of Tables & Figures
TABLE 1 ALLERGY DIAGNOSTIC MARKET: INCLUSIONS & EXCLUSIONS 28 TABLE 2 STANDARD CURRENCY CONVERSION RATES (USD) 30 TABLE 3 IMPACT OF PORTER’S FIVE FORCES IN ALLERGY DIAGNOSTIC MARKET 52 TABLE 4 GDP PERCENTAGE CHANGE, BY COUNTRY, 2021–2030 55 TABLE 5 AVERAGE SELLING PRICE OF ALLERGY DIAGNOSTIC PRODUCTS, BY PRODUCT & SERVICE, 2025 (USD) 60 TABLE 6 AVERAGE PRICING TREND OF ALLERGY DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026 (USD) 60 TABLE 7 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2020–2024 (USD THOUSAND) 61 TABLE 8 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2020–2024 (USD THOUSAND) 62 TABLE 9 KEY MAJOR CONFERENCES AND EVENTS IN ALLERGY DIAGNOSTIC MARKET, JANUARY 2026–DECEMBER 2027 62 TABLE 10 CASE STUDY 1: EXPANDING ACCESS TO ALLERGY DIAGNOSTICS IN EMERGING MARKETS 64 TABLE 11 CASE STUDY 2: SCALING HIGH-THROUGHPUT ALLERGY TESTING IN CENTRALIZED LABORATORIES 65 TABLE 12 CASE STUDY 3: IMPROVING PEDIATRIC ALLERGY DIAGNOSIS THROUGH MULTIPLEX TESTING 65 TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES 66 TABLE 14 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR ALLERGY DIAGNOSTIC 67 TABLE 15 TOP USE CASES AND POTENTIAL IN ALLERGY DIAGNOSTIC MARKET 75 TABLE 16 CASE STUDIES RELATED TO AI IMPLEMENTATION IN ALLERGY DIAGNOSTIC MARKET 75 TABLE 17 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS IN ALLERGY DIAGNOSTIC MARKET 76 TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 21 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 22 MIDDLE EAST & AFRICA AND GCC COUNTRIES: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 23 GLOBAL STANDARDS IN ALLERGY DIAGNOSTIC MARKET 80 TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF ALLERGY DIAGNOSTIC PRODUCTS 82 TABLE 25 KEY BUYING CRITERIA FOR ALLERGY DIAGNOSTIC PRODUCTS 82 TABLE 26 UNMET NEEDS IN ALLERGY DIAGNOSTIC MARKET 83 TABLE 27 ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 86 TABLE 28 ALLERGY DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 87 TABLE 29 ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 88 TABLE 30 ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 88 TABLE 31 ALLERGY DIAGNOSTIC INSTRUMENTS MARKET FOR IMMUNOASSAY ANALYZERS, BY COUNTRY, 2024–2031 (USD MILLION) 90 TABLE 32 ALLERGY DIAGNOSTIC INSTRUMENTS MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2024–2031 (UNITS) 90 TABLE 33 ALLERGY DIAGNOSTIC INSTRUMENTS MARKET FOR LUMINOMETERS, BY COUNTRY, 2024–2031 (USD MILLION) 91 TABLE 34 ALLERGY DIAGNOSTIC INSTRUMENTS MARKET FOR LUMINOMETERS, BY REGION, 2024–2031 (UNITS) 92 TABLE 35 OTHER ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 93 TABLE 36 ALLERGY DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 94 TABLE 37 ADVANTAGES AND LIMITATIONS OF ALLERGY TESTS 96 TABLE 38 ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 96 TABLE 39 ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 97 TABLE 40 ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 98 TABLE 41 ALLERGY DIAGNOSTIC MARKET FOR SKIN PRICK TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 99 TABLE 42 ALLERGY DIAGNOSTIC MARKET FOR PATCH TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 100 TABLE 43 ALLERGY DIAGNOSTIC MARKET FOR OTHER IN VIVO TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 101 TABLE 44 ALLERGY DIAGNOSTIC MARKET FOR IN VITRO TESTS, BY COUNTRY, 2024–2031 (USD MILLION) 103 TABLE 45 ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 105 TABLE 46 ALLERGY DIAGNOSTIC MARKET FOR INHALED ALLERGENS, BY COUNTRY, 2024–2031 (USD MILLION) 106 TABLE 47 SPECIFIC FOOD-INDUCED ALLERGIC CONDITIONS 107 TABLE 48 ALLERGY DIAGNOSTIC MARKET FOR FOOD ALLERGENS, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 49 ALLERGY DIAGNOSTIC MARKET FOR DRUG ALLERGENS, BY COUNTRY, 2024–2031 (USD MILLION) 109 TABLE 50 ALLERGY DIAGNOSTIC MARKET FOR OTHER ALLERGENS, BY COUNTRY, 2024–2031 (USD MILLION) 110 TABLE 51 ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 112 TABLE 52 ALLERGY DIAGNOSTIC MARKET FOR HOSPITAL-BASED LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 53 ALLERGY DIAGNOSTIC MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 54 ALLERGY DIAGNOSTIC MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 55 ALLERGY DIAGNOSTIC MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 56 ALLERGY DIAGNOSTIC MARKET, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 57 NORTH AMERICA: ALLERGY DIAGNOSTIC MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 58 NORTH AMERICA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 122 TABLE 59 NORTH AMERICA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 122 TABLE 60 NORTH AMERICA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 122 TABLE 61 NORTH AMERICA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 123 TABLE 62 NORTH AMERICA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 123 TABLE 63 NORTH AMERICA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 123 TABLE 64 US: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 125 TABLE 65 US: ALLERGY DIAGNOSTICS INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 125 TABLE 66 US: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 125 TABLE 67 US: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 126 TABLE 68 US: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 126 TABLE 69 US: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 126 TABLE 70 CANADA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 127 TABLE 71 CANADA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 127 TABLE 72 CANADA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 128 TABLE 73 CANADA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 128 TABLE 74 CANADA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 128 TABLE 75 CANADA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 129 TABLE 76 EUROPE: ALLERGY DIAGNOSTIC MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 77 EUROPE: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 130 TABLE 78 EUROPE: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130 TABLE 79 EUROPE: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 130 TABLE 80 EUROPE: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 131 TABLE 81 EUROPE: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 131 TABLE 82 EUROPE: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 131 TABLE 83 GERMANY: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 132 TABLE 84 GERMANY: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 133 TABLE 85 GERMANY: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 133 TABLE 86 GERMANY: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 133 TABLE 87 GERMANY: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 134 TABLE 88 GERMANY: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 134 TABLE 89 UK: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 135 TABLE 90 UK: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 91 UK: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 136 TABLE 92 UK: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 93 UK: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 137 TABLE 94 UK: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 137 TABLE 95 FRANCE: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 138 TABLE 96 FRANCE: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 138 TABLE 97 FRANCE: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 138 TABLE 98 FRANCE: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 139 TABLE 99 FRANCE: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 139 TABLE 100 FRANCE: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 139 TABLE 101 ITALY: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 140 TABLE 102 ITALY: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 141 TABLE 103 ITALY: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 141 TABLE 104 ITALY: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 141 TABLE 105 ITALY: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 142 TABLE 106 ITALY: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 142 TABLE 107 SPAIN: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 143 TABLE 108 SPAIN: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 143 TABLE 109 SPAIN: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 144 TABLE 110 SPAIN: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 144 TABLE 111 SPAIN: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 144 TABLE 112 SPAIN: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 145 TABLE 113 REST OF EUROPE: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 145 TABLE 114 REST OF EUROPE: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 146 TABLE 115 REST OF EUROPE: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 146 TABLE 116 REST OF EUROPE: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 146 TABLE 117 REST OF EUROPE: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 147 TABLE 118 REST OF EUROPE: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 147 TABLE 119 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 120 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 149 TABLE 121 ASIA PACIFIC: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 149 TABLE 122 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 149 TABLE 123 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 150 TABLE 124 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 150 TABLE 125 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 150 TABLE 126 CHINA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 151 TABLE 127 CHINA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 152 TABLE 128 CHINA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 152 TABLE 129 CHINA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 152 TABLE 130 CHINA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 153 TABLE 131 CHINA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 153 TABLE 132 JAPAN: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 154 TABLE 133 JAPAN: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 154 TABLE 134 JAPAN: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 155 TABLE 135 JAPAN: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 155 TABLE 136 JAPAN: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 155 TABLE 137 JAPAN: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 156 TABLE 138 INDIA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 157 TABLE 139 INDIA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 157 TABLE 140 INDIA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 157 TABLE 141 INDIA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 158 TABLE 142 INDIA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 158 TABLE 143 INDIA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 158 TABLE 144 SOUTH KOREA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 159 TABLE 145 SOUTH KOREA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 160 TABLE 146 SOUTH KOREA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 160 TABLE 147 SOUTH KOREA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 160 TABLE 148 SOUTH KOREA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 161 TABLE 149 SOUTH KOREA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 161 TABLE 150 AUSTRALIA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 162 TABLE 151 AUSTRALIA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 152 AUSTRALIA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 163 TABLE 153 AUSTRALIA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 154 AUSTRALIA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 163 TABLE 155 AUSTRALIA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 164 TABLE 156 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 165 TABLE 157 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 158 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 165 TABLE 159 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 160 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 166 TABLE 161 REST OF ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 166 TABLE 162 LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 163 LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 167 TABLE 164 LATIN AMERICA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 165 LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 168 TABLE 166 LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 167 LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 169 TABLE 168 LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 169 TABLE 169 BRAZIL: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 170 TABLE 170 BRAZIL: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 171 BRAZIL: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 170 TABLE 172 BRAZIL: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 173 BRAZIL: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 171 TABLE 174 BRAZIL: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 171 TABLE 175 MEXICO: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 172 TABLE 176 MEXICO: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 177 MEXICO: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 173 TABLE 178 MEXICO: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 179 MEXICO: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 174 TABLE 180 MEXICO: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 174 TABLE 181 REST OF LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 175 TABLE 182 REST OF LATIN AMERICA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 175 TABLE 183 REST OF LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 176 TABLE 184 REST OF LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 176 TABLE 185 REST OF LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 176 TABLE 186 REST OF LATIN AMERICA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 177 TABLE 187 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 178 TABLE 188 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 178 TABLE 189 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 178 TABLE 190 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 191 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 179 TABLE 192 MIDDLE EAST & AFRICA: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 179 TABLE 193 GCC COUNTRIES: ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 181 TABLE 194 GCC COUNTRIES: ALLERGY DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 195 GCC COUNTRIES: ALLERGY DIAGNOSTIC MARKET, BY TEST TYPE, 2024–2031 (USD MILLION) 181 TABLE 196 GCC COUNTRIES: ALLERGY DIAGNOSTIC MARKET FOR IN VIVO TESTS, BY TYPE, 2024–2031 (USD MILLION) 182 TABLE 197 GCC COUNTRIES: ALLERGY DIAGNOSTIC MARKET, BY ALLERGEN, 2024–2031 (USD MILLION) 182 TABLE 198 GCC COUNTRIES: ALLERGY DIAGNOSTIC MARKET, BY END USER, 2024–2031 (USD MILLION) 182 TABLE 199 KEY DEVELOPMENTS IN ALLERGY DIAGNOSTIC MARKET, JANUARY 2021–JANUARY 2026 183 TABLE 200 ALLERGY DIAGNOSTIC MARKET: DEGREE OF COMPETITION 186 TABLE 201 ALLERGY DIAGNOSTIC MARKET: REGION FOOTPRINT 189 TABLE 202 ALLERGY DIAGNOSTIC MARKET: PRODUCT & SERVICE FOOTPRINT 190 TABLE 203 ALLERGY DIAGNOSTIC MARKET: TEST TYPE FOOTPRINT 191 TABLE 204 ALLERGY DIAGNOSTIC MARKET: ALLERGEN FOOTPRINT 191 TABLE 205 ALLERGY DIAGNOSTIC MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 193 TABLE 206 ALLERGY DIAGNOSTIC MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY PRODUCT & SERVICE AND REGION 194 TABLE 207 ALLERGY DIAGNOSTIC MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2026 197 TABLE 208 ALLERGY DIAGNOSTIC MARKET: DEALS, JANUARY 2021–JANUARY 2026 197 TABLE 209 ALLERGY DIAGNOSTIC MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2026 198 TABLE 210 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 199 TABLE 211 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 200 TABLE 212 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2026 201 TABLE 213 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–JANUARY 2026 201 TABLE 214 DANAHER CORPORATION: COMPANY OVERVIEW 203 TABLE 215 DANAHER CORPORATION: PRODUCTS OFFERED 204 TABLE 216 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 206 TABLE 217 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 207 TABLE 218 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): COMPANY OVERVIEW 209 TABLE 219 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): PRODUCTS OFFERED 210 TABLE 220 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): DEALS, JANUARY 2021–JANUARY 2026 211 TABLE 221 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): COMPANY OVERVIEW 212 TABLE 222 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): PRODUCTS OFFERED 213 TABLE 223 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): DEALS, JANUARY 2021–JANUARY 2026 214 TABLE 224 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 215 TABLE 225 EUROFINS SCIENTIFIC: PRODUCTS OFFERED 216 TABLE 226 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021–JANUARY 2026 217 TABLE 227 BIOMÉRIEUX SA: COMPANY OVERVIEW 218 TABLE 228 BIOMÉRIEUX SA: PRODUCTS OFFERED 219 TABLE 229 DSM ROYAL (ROMER LABS DIVISION HOLDING GMBH): COMPANY OVERVIEW 220 TABLE 230 DSM ROYAL (ROMER LABS DIVISION HOLDING GMBH): PRODUCTS OFFERED 221 TABLE 231 DSM ROYAL (ROMER LABS DIVISION HOLDING GMBH): DEALS, JANUARY 2021–JANUARY 2026 222 TABLE 232 HOLLISTERSTIER ALLERGY (JUBILANT PHARMA): COMPANY OVERVIEW 223 TABLE 233 HOLLISTERSTIER ALLERGY (JUBILANT PHARMA): PRODUCTS OFFERED 224 TABLE 234 OMEGA DIAGNOSTICS GROUP PLC: COMPANY OVERVIEW 225 TABLE 235 OMEGA DIAGNOSTICS GROUP PLC: PRODUCTS OFFERED 226 TABLE 236 STALLERGENES GREER LTD.: COMPANY OVERVIEW 227 TABLE 237 STALLERGENES GREER LTD.: PRODUCTS OFFERED 227 TABLE 238 STALLERGENES GREER LTD.: DEALS, JANUARY 2021–JANUARY 2026 227 TABLE 239 HOB BIOTECH GROUP CORP., LTD.: COMPANY OVERVIEW 228 TABLE 240 HYCOR BIOMEDICAL: COMPANY OVERVIEW 228 TABLE 241 LINCOLN DIAGNOSTICS, INC.: COMPANY OVERVIEW 229 TABLE 242 R-BIOPHARM AG: COMPANY OVERVIEW 230 TABLE 243 ASTRA BIOTECH GMBH: COMPANY OVERVIEW 231 TABLE 244 ERBA GROUP: COMPANY OVERVIEW 231 TABLE 245 AESKU.GROUP GMBH: COMPANY OVERVIEW 232 TABLE 246 ACON LABORATORIES, INC.: COMPANY OVERVIEW 232 TABLE 247 ALCIT INDIA PVT. LTD.: COMPANY OVERVIEW 233 TABLE 248 BIOPANDA REAGENTS LTD.: COMPANY OVERVIEW 233 TABLE 249 BIOSIDE S.R.L.: COMPANY OVERVIEW 234 TABLE 250 CREATIVE DIAGNOSTIC MEDICARE PVT. LTD.: COMPANY OVERVIEW 234 TABLE 251 DST DIAGNOSTISCHE SYSTEME & TECHNOLOGIEN GMBH: COMPANY OVERVIEW 235 TABLE 252 DR. FOOKE LABORATORIEN GMBH: COMPANY OVERVIEW 235 TABLE 253 ALLERGY DIAGNOSTIC MARKET: STUDY ASSUMPTIONS 248 TABLE 254 ALLERGY DIAGNOSTIC MARKET: RISK ANALYSIS 248 FIGURE 1 ALLERGY DIAGNOSTIC MARKET SEGMENTATION & REGIONAL SCOPE 29 FIGURE 2 ALLERGY DIAGNOSTIC MARKET: YEARS CONSIDERED 30 FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS 32 FIGURE 4 ALLERGY DIAGNOSTIC MARKET SIZE, 2026–2031 (USD MILLION) 33 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN ALLERGY DIAGNOSTIC MARKET 34 FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF ALLERGY DIAGNOSTIC MARKET 35 FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN ALLERGY DIAGNOSTIC MARKET, BY PRODUCT & SERVICE, TEST TYPE, END USER, AND REGION (2025) 36 FIGURE 8 NORTH AMERICA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 37 FIGURE 9 INCREASING GOVERNMENT INITIATIVES AND RISING INVESTMENTS TO IMPROVE MARKET GROWTH 38 FIGURE 10 CHINA AND HOSPITAL-BASED LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 39 FIGURE 11 INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 40 FIGURE 12 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE FROM 2024 TO 2031 41 FIGURE 13 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD 41 FIGURE 14 ALLERGY DIAGNOSTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42 FIGURE 15 ALLERGY DIAGNOSTIC MARKET: PORTER’S FIVE FORCES ANALYSIS 53 FIGURE 16 ALLERGY DIAGNOSTIC MARKET: SUPPLY CHAIN ANALYSIS 57 FIGURE 17 ALLERGY DIAGNOSTIC MARKET: VALUE CHAIN ANALYSIS 58 FIGURE 18 ALLERGY DIAGNOSTIC MARKET: ECOSYSTEM ANALYSIS 59 FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN ALLERGY DIAGNOSTIC MARKET 63 FIGURE 20 FUNDING AND NUMBER OF DEALS IN ALLERGY DIAGNOSTIC MARKET (USD MILLION) 64 FIGURE 21 NUMBER OF PATENTS PUBLISHED IN ALLERGY DIAGNOSTIC MARKET, JANUARY 2016─JANUARY 2026 72 FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR ALLERGY DIAGNOSTIC (JANUARY 2015−JANUARY 2026) 73 FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF ALLERGY DIAGNOSTIC PRODUCTS 81 FIGURE 24 KEY BUYING CRITERIA FOR ALLERGY DIAGNOSTIC PRODUCTS 82 FIGURE 25 NORTH AMERICA: ALLERGY DIAGNOSTIC MARKET SNAPSHOT 121 FIGURE 26 ASIA PACIFIC: ALLERGY DIAGNOSTIC MARKET SNAPSHOT 148 FIGURE 27 REVENUE ANALYSIS OF TOP PLAYERS IN ALLERGY DIAGNOSTIC MARKET, 2021–2025 (USD MILLION) 184 FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ALLERGY DIAGNOSTIC MARKET, 2025 185 FIGURE 29 ALLERGY DIAGNOSTIC MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 188 FIGURE 30 ALLERGY DIAGNOSTIC MARKET: COMPANY FOOTPRINT 189 FIGURE 31 ALLERGY DIAGNOSTIC MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 193 FIGURE 32 EV/EBITDA OF KEY VENDORS 195 FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 195 FIGURE 34 ALLERGY DIAGNOSTIC MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 196 FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 200 FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT 204 FIGURE 37 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 207 FIGURE 38 CANON, INC. (MINARIS MEDICAL AMERICA, INC.): COMPANY SNAPSHOT 210 FIGURE 39 REVVITY, INC. (EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG): COMPANY SNAPSHOT 213 FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 216 FIGURE 41 BIOMÉRIEUX SA: COMPANY SNAPSHOT 219 FIGURE 42 DSM ROYAL (ROMER LABS DIVISION HOLDING GMBH): COMPANY SNAPSHOT 221 FIGURE 43 HOLLISTERSTIER ALLERGY (JUBILANT PHARMA): COMPANY SNAPSHOT 224 FIGURE 44 OMEGA DIAGNOSTICS GROUP PLC: COMPANY SNAPSHOT 226 FIGURE 45 ALLERGY DIAGNOSTIC MARKET: RESEARCH DESIGN 236 FIGURE 46 ALLERGY DIAGNOSTIC MARKET: KEY DATA FROM SECONDARY SOURCES 238 FIGURE 47 ALLERGY DIAGNOSTIC MARKET: PRIMARY SOURCES 238 FIGURE 48 ALLERGY DIAGNOSTIC MARKET: KEY DATA FROM PRIMARY SOURCES 239 FIGURE 49 ALLERGY DIAGNOSTIC MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 240 FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY/DEMAND-SIDE PARTICIPANTS 240 FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION 241 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS, BY END USER, DESIGNATION, AND REGION 241 FIGURE 53 ALLERGY DIAGNOSTIC MARKET SIZE ESTIMATION 242 FIGURE 54 REVENUE SHARE ANALYSIS ILLUSTRATION: THERMO FISHER SCIENTIFIC INC. (2025) 243 FIGURE 55 SUPPLY-SIDE ANALYSIS OF KEY PLAYERS IN ALLERGY DIAGNOSTIC MARKET (2025) 243 FIGURE 56 ALLERGY DIAGNOSTIC MARKET: TOP-DOWN APPROACH 244 FIGURE 57 ALLERGY DIAGNOSTIC MARKET: CAGR PROJECTIONS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2031) 246 FIGURE 58 ALLERGY DIAGNOSTIC MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 246 FIGURE 59 ALLERGY DIAGNOSTIC MARKET: DATA TRIANGULATION 247

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們